Drug Shortage Report for POTASSIUM PHOSPHATES
| Report ID | 168553 |
| Drug Identification Number | 00804789 |
| Brand name | POTASSIUM PHOSPHATES |
| Common or Proper name | POTASSIUM PO4 |
| Company Name | SANDOZ CANADA INCORPORATED |
| Market Status | MARKETED |
| Active Ingredient(s) | POTASSIUM PHOSPHATE DIBASIC POTASSIUM PHOSPHATE MONOBASIC |
| Strength(s) | 236MG 224MG |
| Dosage form(s) | LIQUID |
| Route of administration | INTRAVENOUS INTRAVENOUS |
| Packaging size | 10ML 10LIVI |
| ATC code | B05XA |
| ATC description | I.V. SOLUTION ADDITIVES |
| Reason for shortage | Requirements related to complying with good manufacturing practices. |
| Anticipated start date | |
| Actual start date | 2023-01-16 |
| Estimated end date | 2023-05-15 |
| Actual end date | 2023-05-09 |
| Shortage status | Resolved |
| Updated date | 2023-05-30 |
| Company comments | Baxter item : 6750. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 110 RUE DE LAUZON BOUCHERVILLE, QUEBEC CANADA J4B 1E6 |
| Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v3 | 2022-09-03 | English | Compare |
| v2 | 2022-09-02 | French | Compare |
| v1 | 2022-09-02 | English | Compare |